Total Payments
$27,716
2024 Payments
$4,198
Companies
22
Transactions
262
Medicare Patients
12,297
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$19,358 (69.8%)
Food & Beverage$5,803 (20.9%)
Consulting$2,200 (7.9%)
Travel$193.36 (0.7%)
Education$161.09 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,358 | 19 | 69.8% |
| Food and Beverage | $5,803 | 225 | 20.9% |
| Consulting Fee | $2,200 | 1 | 7.9% |
| Travel and Lodging | $193.36 | 3 | 0.7% |
| Education | $161.09 | 14 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $18,786 | 78 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $3,430 | 43 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $2,954 | 26 | $0 (2024) |
| Amgen Inc. | $415.83 | 18 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $407.23 | 19 | $0 (2024) |
| Vifor Pharma, Inc. | $359.57 | 15 | $0 (2024) |
| Travere Therapeutics, Inc. | $329.51 | 19 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $190.32 | 9 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $149.35 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $135.71 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,198 | 100 | Mallinckrodt Hospital Products Inc. ($2,582) |
| 2023 | $1,308 | 63 | Mallinckrodt Hospital Products Inc. ($323.75) |
| 2022 | $3,153 | 54 | AstraZeneca Pharmaceuticals LP ($2,310) |
| 2021 | $4,721 | 11 | AstraZeneca Pharmaceuticals LP ($4,721) |
| 2020 | $6,893 | 13 | AstraZeneca Pharmaceuticals LP ($6,893) |
| 2019 | $7,341 | 19 | AstraZeneca Pharmaceuticals LP ($4,320) |
| 2017 | $102.21 | 2 | Amgen Inc. ($101.67) |
All Payment Transactions
262 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 12/20/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 12/20/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 12/19/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: CRITICAL CARE | ||||||
| 12/18/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $18.97 | General |
| Category: NEPHROLOGY | ||||||
| 12/04/2024 | Recor Medical Inc | PARADISE RENAL DENERVATION SYSTEM (Device) | Food and Beverage | Cash or cash equivalent | $23.97 | General |
| Category: Endovascular | ||||||
| 12/02/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: NEPHROLOGY | ||||||
| 11/21/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: CRITICAL CARE | ||||||
| 11/20/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $35.47 | General |
| 11/13/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.34 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: CRITICAL CARE | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $26.71 | General |
| Category: Immunology | ||||||
| 10/30/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $24.55 | General |
| Category: Nephrology | ||||||
| 10/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: DIABETES | ||||||
| 10/28/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.38 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/28/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/23/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: CRITICAL CARE | ||||||
| 10/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/14/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Diabetes | ||||||
| 10/04/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: NEPHROLOGY | ||||||
| 10/01/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $25.09 | General |
| 10/01/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $5.34 | General |
| 09/26/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: CRITICAL CARE | ||||||
| 09/25/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/24/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: Inflammation/Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 2,646 | 5,351 | $1.4M | $399,577 |
| 2022 | 27 | 3,395 | 5,912 | $1.8M | $519,936 |
| 2021 | 25 | 3,422 | 5,737 | $1.8M | $514,648 |
| 2020 | 22 | 2,834 | 4,986 | $1.5M | $438,551 |
Total Patients
12,297
Total Services
21,986
Medicare Billing
$1.9M
Procedure Codes
101
All Medicare Procedures & Services
101 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 58 | 303 | $264,813 | $79,849 | 30.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 218 | 826 | $157,601 | $49,701 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 328 | 543 | $167,977 | $47,597 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 656 | 798 | $173,485 | $45,373 | 26.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 206 | 550 | $58,520 | $20,952 | 35.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 38 | 93 | $67,132 | $20,401 | 30.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 188 | 224 | $69,530 | $19,291 | 27.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 144 | 169 | $59,532 | $16,540 | 27.8% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 91 | 91 | $67,933 | $14,617 | 21.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 72 | 342 | $52,152 | $11,748 | 22.5% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 11 | 54 | $38,939 | $11,589 | 29.8% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 38 | 48 | $31,573 | $9,866 | 31.2% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 61 | 291 | $45,710 | $9,504 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 77 | 77 | $31,071 | $7,938 | 25.5% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 42 | 46 | $22,335 | $6,486 | 29.0% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 42 | 98 | $17,462 | $5,401 | 30.9% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 102 | 104 | $35,583 | $4,918 | 13.8% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 50 | 137 | $17,291 | $3,899 | 22.5% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2023 | 14 | 21 | $10,317 | $3,093 | 30.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $9,658 | $2,662 | 27.6% |
| 90970 | Dialysis services, per day, less than full month service (20 years or older) | Office | 2023 | 17 | 339 | $7,960 | $2,341 | 29.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 22 | $6,020 | $2,020 | 33.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 31 | 32 | $6,990 | $1,997 | 28.6% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 67 | 67 | $19,966 | $1,307 | 6.5% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2023 | 40 | 40 | $2,156 | $490.01 | 22.7% |
About Dr. Abdul Zanabli, MD
Dr. Abdul Zanabli, MD is a Internal Medicine healthcare provider based in S Charleston, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487752093.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Abdul Zanabli, MD has received a total of $27,716 in payments from pharmaceutical and medical device companies, with $4,198 received in 2024. These payments were reported across 262 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,358).
As a Medicare-enrolled provider, Zanabli has provided services to 12,297 Medicare beneficiaries, totaling 21,986 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 101 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location S Charleston, WV
- Active Since 09/20/2006
- Last Updated 12/05/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1487752093
Products in Payments
- LOKELMA (Drug) $15,948
- JYNARQUE (Drug) $3,385
- TERLIVAZ (Drug) $2,902
- FARXIGA (Drug) $2,703
- Kerendia (Drug) $407.23
- Veltassa (Drug) $300.85
- JARDIANCE (Drug) $298.72
- TARPEYO (Drug) $149.35
- KRYSTEXXA (Biological) $120.68
- Parsabiv (Drug) $115.61
- Parsabiv (Biological) $101.67
- IBSRELA (Drug) $78.23
- TAVNEOS (Drug) $77.87
- SYSTEM ONE (Device) $71.62
- Fabhalta (Drug) $69.03
- SAMSCA (Drug) $61.20
- ACTHAR (Biological) $51.17
- LifeVest (Device) $50.00
- PARADISE RENAL DENERVATION SYSTEM (Device) $47.94
- BENLYSTA (Biological) $45.95
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.